Cara Therapeutics | CARA - Operating Profit


Cara Therapeutics reported $-7.05M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Cassava Sciences USD -11.17M 2.38M Mar/2026
Chugai Pharma JPY 160.86B 2.09B Jun/2026
Cipla INR 8.88B 2.74B Jun/2026
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD -9.02M 65.06M Mar/2026
CSL USD 2.64B 1.97B Dec/2025
Grifols EUR 320.55M 91.01M Dec/2025
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
J&J USD 7.48B 860M Jun/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Pacira USD 9.96M 5.33M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
RedHill Biopharma USD -4.22M 1.8M Jun/2024
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024